• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

立体定向体部放射治疗对寡转移性乳腺癌全身治疗线改变的影响。

Impact of stereotactic body radiation therapy on systemic therapeutic line change in oligometastatic breast cancer.

作者信息

Leblanc Julie, de Nonneville Alexandre, Nicolas Camille, Gonçalves Anthony, Favrel Véronique, Tyran Marguerite, Guenole Morgan, Varela Leonel, Gonzague Laurence, Tallet Agnès, Petit Claire

机构信息

Aix-Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes, Department of Radiotherapy, CRCM, Marseille, France.

Aix-Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes, Department of Medical Oncology, CRCM, Marseille, France; Aix-Marseille Univ, CNRS, INSERM, CRCM, Marseille, France.

出版信息

Breast. 2025 Jul 21;83:104546. doi: 10.1016/j.breast.2025.104546.

DOI:10.1016/j.breast.2025.104546
PMID:40737892
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12329079/
Abstract

• SBRT is widely used in oligometastatic breast cancer despite limited evidence. • SBRT delayed systemic therapeutic line change by over 1 year in our cohort. • Our study may help to identify patients most likely to benefit from SBRT. • SBRT is a well-tolerated treatment with limited toxicity. • Randomized trials are needed to assess the benefit of SBRT in terms of survival.

摘要

• 尽管证据有限，但立体定向体部放疗（SBRT）仍广泛应用于寡转移乳腺癌。

• 在我们的队列中，SBRT将全身治疗线的改变推迟了1年多。

• 我们的研究可能有助于确定最有可能从SBRT中获益的患者。

• SBRT是一种耐受性良好、毒性有限的治疗方法。

• 需要进行随机试验来评估SBRT在生存方面的益处。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f41/12329079/69680f09a2e5/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f41/12329079/364d8916b0d9/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f41/12329079/c83731a1d07c/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f41/12329079/89e2d9baea09/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f41/12329079/69680f09a2e5/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f41/12329079/364d8916b0d9/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f41/12329079/c83731a1d07c/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f41/12329079/89e2d9baea09/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f41/12329079/69680f09a2e5/gr4.jpg

相似文献

1
Impact of stereotactic body radiation therapy on systemic therapeutic line change in oligometastatic breast cancer.立体定向体部放射治疗对寡转移性乳腺癌全身治疗线改变的影响。
Breast. 2025 Jul 21;83:104546. doi: 10.1016/j.breast.2025.104546.
2
Stereotactic Body Radiation Therapy for Oligometastatic Recurrent Esophageal Squamous Cell Carcinoma: A Retrospective Cohort Study From a Single Tertiary Center.立体定向体部放射治疗寡转移复发性食管鳞状细胞癌：来自单一三级中心的回顾性队列研究
Cancer Rep (Hoboken). 2025 Jun;8(6):e70248. doi: 10.1002/cnr2.70248.
3
The Effectiveness and Safety of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Oligoprogressive Breast Cancer: A Systematic Review.立体定向体部放疗（SBRT）治疗寡进展性乳腺癌的有效性和安全性：系统评价。
Curr Oncol. 2023 Jul 21;30(7):6976-6985. doi: 10.3390/curroncol30070505.
4
Review of Prospective Trials Assessing the Role of Stereotactic Body Radiation Therapy for Metastasis-directed Treatment in Oligometastatic Genitourinary Cancers.评估立体定向体部放射治疗在寡转移泌尿生殖系统癌症转移灶定向治疗中作用的前瞻性试验综述。
Eur Urol Oncol. 2023 Feb;6(1):28-38. doi: 10.1016/j.euo.2022.09.007. Epub 2022 Oct 22.
5
Impacts of co-mutations in oligometastatic and oligoprogressive non-small cell lung cancer with mutations-a narrative review of the current literature.寡转移和寡进展性非小细胞肺癌共突变与突变的影响——当前文献的叙述性综述
Transl Lung Cancer Res. 2025 May 30;14(5):1848-1861. doi: 10.21037/tlcr-2024-1121. Epub 2025 May 28.
6
A Prospective Study of Stereotactic Body Radiation Therapy in Oligometastatic Renal Cell Carcinoma.寡转移肾细胞癌立体定向体部放射治疗的前瞻性研究
Int J Radiat Oncol Biol Phys. 2025 May 30. doi: 10.1016/j.ijrobp.2025.05.059.
7
Stereotactic body radiation therapy in the treatment of cancer patients with oligometastatic disease: a real world study.立体定向体部放射治疗在寡转移癌患者治疗中的应用：一项真实世界研究
Clin Transl Oncol. 2023 Jan;25(1):199-206. doi: 10.1007/s12094-022-02923-7. Epub 2022 Sep 6.
8
Metastasectomy versus stereotactic body radiotherapy for patients with oligometastatic colorectal lung metastases: a systematic review.寡转移性结直肠癌肺转移患者的肺转移灶切除术与立体定向体部放疗：一项系统评价
Eur J Surg Oncol. 2025 Aug;51(8):110056. doi: 10.1016/j.ejso.2025.110056. Epub 2025 Apr 17.
9
Treatment of oligometastatic lung cancer with brain metastases using stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT).使用立体定向放射外科（SRS）和立体定向体部放射治疗（SBRT）治疗伴有脑转移的寡转移肺癌。
Clin Transl Radiat Oncol. 2019 Dec 11;21:32-35. doi: 10.1016/j.ctro.2019.12.001. eCollection 2020 Mar.
10
Metastasis-directed stereotactic body radiation therapy in the management of oligometastatic head and neck cancer.寡转移头颈部癌转移灶定向立体定向放疗的管理。
J Cancer Res Clin Oncol. 2021 May;147(5):1307-1313. doi: 10.1007/s00432-021-03518-5. Epub 2021 Jan 20.

本文引用的文献

1
Treatment of oligometastatic breast cancer: The role of patient selection.寡转移性乳腺癌的治疗：患者选择的作用。
Breast. 2025 Feb;79:103839. doi: 10.1016/j.breast.2024.103839. Epub 2024 Nov 14.
2
Thoracic Radiotherapy Improves the Survival in Patients With -Mutated Oligo-Organ Metastatic Non-Small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Multicenter, Randomized, Controlled, Phase III Trial.胸部放疗可改善接受表皮生长因子受体酪氨酸激酶抑制剂治疗的KRAS突变型寡器官转移非小细胞肺癌患者的生存率：一项多中心、随机、对照、III期试验。
J Clin Oncol. 2025 Feb;43(4):412-421. doi: 10.1200/JCO.23.02075. Epub 2024 Oct 7.
3
Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial.
曲妥珠单抗德鲁昔单抗用于伴或不伴脑转移的HER2阳性晚期乳腺癌：一项3b/4期试验
Nat Med. 2024 Dec;30(12):3717-3727. doi: 10.1038/s41591-024-03261-7. Epub 2024 Sep 13.
4
Global burden of breast cancer and attributable risk factors in 204 countries and territories, from 1990 to 2021: results from the Global Burden of Disease Study 2021.1990年至2021年204个国家和地区的乳腺癌全球负担及可归因风险因素：全球疾病负担研究2021的结果
Biomark Res. 2024 Aug 26;12(1):87. doi: 10.1186/s40364-024-00631-8.
5
Stereotactic Ablative Radiation for Oligoprogressive Cancers: Results of the Randomized Phase 2 STOP Trial.立体定向消融放疗用于寡进展性癌症：随机2期STOP试验结果
Int J Radiat Oncol Biol Phys. 2025 Jan 1;121(1):28-38. doi: 10.1016/j.ijrobp.2024.08.031. Epub 2024 Aug 19.
6
Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A Multicenter, Randomized Phase II Trial.寡转移胰腺导管腺癌（EXTEND）系统治疗中加入转移灶导向治疗：一项多中心、随机的 II 期试验。
J Clin Oncol. 2024 Nov 10;42(32):3795-3805. doi: 10.1200/JCO.24.00081. Epub 2024 Aug 5.
7
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.2022 年全球癌症统计数据：全球 185 个国家和地区 36 种癌症的发病率和死亡率全球估计数。
CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4.
8
Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study.标准治疗系统疗法联合或不联合立体定向体部放疗治疗寡进展性乳腺癌或非小细胞肺癌患者（放疗阻断寡进展[CURB]研究）：一项开放标签、随机、对照、2 期研究。
Lancet. 2024 Jan 13;403(10422):171-182. doi: 10.1016/S0140-6736(23)01857-3. Epub 2023 Dec 14.
9
Stereotactic Body Radiation Therapy and Abiraterone Acetate for Patients Affected by Oligometastatic Castrate-Resistant Prostate Cancer: A Randomized Phase II Trial (ARTO).寡转移去势抵抗性前列腺癌患者接受立体定向体部放疗联合醋酸阿比特龙治疗的随机Ⅱ期临床试验（ARTO）
J Clin Oncol. 2023 Dec 20;41(36):5561-5568. doi: 10.1200/JCO.23.00985. Epub 2023 Sep 21.
10
Ten-Year Outcomes of Stereotactic Body Radiotherapy for Oligometastatic Breast Cancer: Does Synchronous Oligometastatic Breast Cancer Benefit?寡转移乳腺癌立体定向体部放疗的 10 年结果：同步寡转移乳腺癌是否获益？
Clin Oncol (R Coll Radiol). 2023 Nov;35(11):736-743. doi: 10.1016/j.clon.2023.08.006. Epub 2023 Aug 31.